On Tuesday, Stifel initiated coverage on shares of Inari Medical Inc. (NASDAQ: NARI) with a Hold rating and a price target set at $50. The firm acknowledges several positive market catalysts that could enhance the penetration of Mechanical Thrombectomy procedures, which Inari Medical specializes in.
However, Stifel remains cautious, citing survey results that predict a stable to declining market share for Inari Medical in the coming years. This outlook presents a challenge in actively recommending the stock at present.
Despite the current market positioning of Inari Medical at relative and absolute discounts, Stifel's decision to start with a Hold rating reflects a balanced view of potential market growth against competitive and regulatory challenges. The firm points to upcoming data, mostly sponsored by Inari Medical, which could stimulate underlying market expansion. Nevertheless, the competitive landscape is expected to evolve, and this could influence future recommendations.
Stifel also acknowledges the ongoing investigation by the Department of Justice (DOJ) into Inari Medical. While their preliminary assessment suggests that the investigation may not significantly disrupt the company's operations, the absence of a clear timeline for a resolution adds to the uncertainty.
The firm indicates that changes in the competitive dynamics, or increased confidence in the progression of "emerging" opportunities, could potentially lead to a more favorable view of Inari Medical's shares. For now, Stifel maintains a cautious stance, incorporating these various factors into their Hold rating and price target for the medical device company.
In other recent news, Inari Medical has been the subject of several analyst ratings. Piper Sandler has reaffirmed a Neutral rating on Inari Medical, citing the results of a recent animal study investigating the company's FlowSaver technology. Despite an increase in plasma free hemoglobin levels after multiple uses of the technology, Piper Sandler maintained a cautious approach, considering the technology's substantial history of clinical use and the FDA's rigorous testing.
Deutsche Bank (ETR:DBKGn) has reiterated a Buy rating on Inari Medical, expressing confidence in the company's growth potential despite recent safety concerns regarding two of the company's products involved in venous clot removal. Truist Securities, on the other hand, has adjusted its price target for Inari Medical, decreasing it to $55 from the previous $60, while maintaining a Hold rating on the company's stock. This adjustment follows Inari Medical's second-quarter earnings report, which showed a modest revenue beat and a raised forecast.
In other developments, Inari Medical announced an unexpected Chief Financial Officer transition, with Kevin Strange set to replace Mitch Hill. The company also reported approximately 17% growth in its core US Venous Thromboembolism business. However, the operational loss was larger than expected, which may raise concerns among investors.
InvestingPro Insights
Inari Medical Inc. (NASDAQ: NARI) continues to navigate a complex market landscape, and real-time data from InvestingPro underscores some of the financial nuances that investors should consider. The company boasts an impressive gross profit margin of 87.15% over the last twelve months as of Q2 2024, reflecting its strong operational efficiency in generating revenue from its sales. Despite this, Inari Medical operates with a negative P/E ratio of -44.93, with a further adjusted P/E ratio for the last twelve months as of Q2 2024 at -69.48, signaling that the market has concerns about the company's profitability in the near term.
InvestingPro Tips highlight that while Inari Medical maintains a moderate level of debt, analysts have revised their earnings downwards for the upcoming period, and net income is expected to drop this year. Additionally, they do not anticipate the company will be profitable within the year, and it's worth noting that the company has not been profitable over the last twelve months. Inari Medical is also trading at a high Price/Book multiple of 6.06, which may raise questions about valuation among investors. Moreover, the company does not pay a dividend, which could influence investment decisions for income-focused shareholders.
For investors seeking a more comprehensive analysis, there are additional InvestingPro Tips available, which could offer deeper insights into Inari Medical's financial health and market potential. It's important to consider these metrics and tips in conjunction with the broader market and competitive dynamics discussed in the article to form a well-rounded view of the investment opportunity Inari Medical presents.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.